Chimeric retrovirus/adenovirus system
AssigneeThe UAB Research Foundation
InventorDavid T. Curiel
Life of this patent
Estimating the term…
Abstract
The present invention provides a chimeric viral vector system having a highly efficient in vivo gene delivery to cells after vascular administration and an intergrative capacity of heterologous gene sequences for stable genetic modification of cells after transduction. In this chimeric vector, an adenoviral vector is employed to deliver retroviral functions to a cell for local, in situ production of retroviral particles inside the cell by the construction of replication-defective adenoviral vectors which contain either retroviral “packaging” functions (retroviral genes gag, pol, env) and retroviral “vector” functions (retroviral LTR sequences flanking the “therapeutic” gene).
Claims10
A chimeric adenoviral/retroviral vector composition, wherein said chimeric adenoviral/retroviral vector composition comprises:
- (a) a replication-deficient adenoviral vector containing retroviral vector functions;
- and
- (b) at least one replication-deficient adenoviral vector containing retroviral packaging functions.
A method of stably transducing target cells, comprising the step of:
- co-transducing said target cells with a chimeric adenoviral/retroviral vector composition, said composition comprising:
- (a) a replication-deficient adenoviral vector containing retroviral vector functions;
- and
- (b) a replication-deficient adenoviral vector containing retroviral packaging functions, wherein expression of the genes encoded by said adenoviral vectors results in the production of retrovirus particles that would infect neighboring cells and stably integrate into said cells' genomic DNA.
Dependencies are inferred from the claim text.